Skip to main content

Table 3 Result of subsequent autologous stem cell transplantation

From: Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma

  Cyclophosphamide
(n = 57)
Etoposide
(n = 56)
P value
Conditioning regimen, n (%)    < 0.001
 High-dose melphalan 48 (84.2) 9 (16.1)  
 Melphalan with another agent 9 (15.8) 27 (48.2)  
 Busulfan-Thiotepa 0 (0.0) 20 (35.7)  
Median infused CD34+ cells (× 106 CD34+/kg) 5.71 (1.85 ~  12.60) 16.15 (7.10 ~  39.00) < 0.001
Post PBSC infusion hospitalization duration, days (range) 15 (13~65) 14 (12~54) 0.005
Time to neutrophil engraftment (>  0.5 × 109/L), days 11 (8 ~  17) 10 (8 ~  15) 0.292
Time to platelet engraftment (>  20 × 109/L), days 9 (6 ~  32) 12 (7 ~  13) 0.055
Median number of platelet transfusions support during transplantation (range) 4 (1~12) 2 (0~8) < 0.001
Pre-engraftment complications, n (%)
 Neutropenic fever 41 (73.2) 36 (67.9) 0.674
 Hepatic veno-occlusive disease 0 (0.0) 0 (0.0)  
 Hemorrhagic cystitis 0 (0.0) 0 (0.0)  
 Engraftment syndrome 6 (11.1) 7 (12.5) 1.000
 Early graft failure 0 (0.0) 0 (0.0)  
 Treatment-related mortality 1 (1.8) 2 (3.6) 0.618